Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -18.17% is 125% below its 5-year average of 73.56%, around the middle of its 5-year range (-109.20%–100.00%).
162.34% below its 12-month average of 29.15%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 95.45%.
GROSS MARGIN
-18.17%
GROSS MARGIN AVG TTM
29.15%
GROSS MARGIN AVG 3Y
74.71%
GROSS MARGIN AVG 5Y
73.56%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-162.34%
CURRENT VS 3Y AVG
-124.32%
CURRENT VS 5Y AVG
-124.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-144.10%
vs the sector median at left
Market Cap
$632.16M
Gross Margin
-58.05%
TTM Avg
20.98%
3Y Avg
10.49%
5Y Avg
14.13%
Market Cap
$634.30M
Gross Margin
84.52%
TTM Avg
76.56%
3Y Avg
85.05%
5Y Avg
87.20%
Market Cap
$638.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$619.15M
Gross Margin
66.63%
TTM Avg
64.65%
3Y Avg
65.95%
5Y Avg
64.74%
Market Cap
$656.59M
Gross Margin
91.05%
TTM Avg
-190849.07%
3Y Avg
-96132.87%
5Y Avg
-64176.88%
Market Cap
$657.89M
Gross Margin
15.69%
TTM Avg
15.20%
3Y Avg
15.20%
5Y Avg
15.20%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $630.63M | -18.17% | 29.15% | 74.71% | 73.56% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -58.05% | 20.98% | 10.49% | 14.13% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 84.52% | 76.56% | 85.05% | 87.20% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | 66.63% | 64.65% | 65.95% | 64.74% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | 0.00% | 0.00% | 0.00% | 0.00% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | 15.69% | 15.20% | 15.20% | 15.20% |
| Annexon, Inc. (ANNX)vs › | $660.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 99.76% | 98.92% | 99.03% | 96.38% |
Gross Margin
-18.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 95.45% |
| 2026-03-31 | 58.33% |
| 2025-12-31 | 7.88% |
| 2025-09-30 | -109.20% |
| 2025-06-30 | 93.28% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 11.56% |
| 2023-06-30 | 30.03% |
| 2023-03-31 | 74.18% |
| 2022-12-31 | 90.73% |
| 2022-09-30 | 34.85% |
| 2022-06-30 | 37.64% |
| 2022-03-31 | 58.38% |
| 2021-12-31 | 78.87% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
